This study is looking at whether using a device called myAirvo 3, which provides high-flow warmed and humidified air through your nose (High Flow Nasal Therapy or HFNT), can help people with moderate to very severe Chronic Obstructive Pulmonary Disease (COPD) stay healthier at home. You might be able to join if you are 30 years or older, have moderate to very severe COPD, and have recently been hospitalized for a severe COPD flare-up. The main goal is to see if using myAirvo 3 increases the time until your first moderate or severe COPD flare-up, or death, over one year. The study also looks at how myAirvo 3 affects hospitalizations, quality of life, and breathing.

Study design

This is a randomized controlled study with 642 participants, comparing myAirvo 3 plus usual COPD care to usual COPD care alone.

What's involved

If you participate, you will use the myAirvo 3 device if assigned to that group, and use a pulse oximeter daily to measure your heart rate and oxygen levels, entering the data on a smartphone.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for at least one year, and up to two years, to track outcomes like exacerbations and mortality.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.